BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

Blood

Volumn 111, Issue 5, 2008, Pages 2904-2908

  Ban, Kechen ^a   Gao, Yin ^a   Amin, Hesham M ^a   Howard, Adrienne ^a   Miller, Claudia ^a   Lin, Quan ^a   Leng, Xiaohong ^a   Munsell, Mark ^a   Bar Eli, Menashe ^a   Arlinghaus, Ralph B ^a   Chandra, Joya ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MESSENGER RNA; PROTEIN KINASE FYN; SHORT HAIRPIN RNA; FYN PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TISSUE MICROARRAY; UPREGULATION; ANIMAL; BLAST CELL CRISIS; CELL PROLIFERATION; CELL STRAIN K 562; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY;

ANIMALS; BLAST CRISIS; CELL PROLIFERATION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, SCID; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-FYN; PYRIMIDINES; UP-REGULATION;

EID: 41949101422     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-05-091769     Document Type: Article

References (15)

1. Van Etten RA. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med. 2007;204:461-465.
2. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004;23:7990-8000.
3. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src kinases p53/ 56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 1996;56:3589-3596.
4. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:453-461.
5. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690-698.
6. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med. 2004;10:1187-1189.
7. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103:2794-2799.
8. Juric D, Lacayo NJ, Ramsey MC, et al. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol. 2007;25:1341-1349.
9. Chandra J, Tracy J, Loegering D, et al. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006;107:2501-2506.
10. Klucher KM, Lopez DV, Daley GQ. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 1998;91:3927-3934.
11. Chandra J, Hackbarth J, Le S, et al. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood. 2003; 102:4512-4519.
12. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
13. Mow BM, Chandra J, Svingen PA, et al. Effects of the Bcr/abl kinase inhibitors STI571 and ada- phostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002;99:664-671.
14. Meyn MA III, Wilson MB, Abdi FA, et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem. 2006;281:30907-30916.
15. Doggrell SA. BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin Investig Drugs. 2005;14:89-91.